Altimmune ALT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Altimmune’s reported figures.
Based on trailing twelve months.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's return on equity?
- Altimmune (ALT) reported return on equity of -42.7% in Q1 2026.
- How has Altimmune's return on equity changed year-over-year?
- Altimmune's return on equity increased by 25.4% year-over-year, from -57.3% to -42.7%.
- What is the long-term trend for Altimmune's return on equity?
- Over 5 years (2020 to 2025), Altimmune's return on equity has grown at a 6.9% compound annual growth rate (CAGR), from -36.1% to -50.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.